Atrovastatin-PEG3-FITC

Atrovastatin-PEG3-FITC (compound S31) is a KRAS-PDEδ interaction inhibitor. Atrovastatin-PEG3-FITC acts as a ligand in fluorescence anisotropy assay[1][2].

Product Specifications

CAS Number

[1440755-31-6]

UNSPSC

12352005

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/atrovastatin-peg3-fitc.html

Purity

98.17

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1OC2(C3=CC=C(O)C=C3OC4=CC(O)=CC=C42)C5=CC=C(NC(NCCCOCCOCCOCCCNC(C[C@H](O)C[C@H](O)CCN6C(C7=CC=C(C=C7)F)=C(C8=CC=CC=C8)C(C(NC9=CC=CC=C9)=O)=C6C(C)C)=O)=S)C=C51

Molecular Formula

C64H68FN5O12S

Molecular Weight

1150.31

References & Citations

[1]Gunther Zimmermann, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signaling. Nature. 2013 May 30;497 (7451) :638-42.|[2]Yan Jiang, et al. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors. J Med Chem. 2017 Nov 22;60 (22) :9400-9406.